 Lexaria Bioscience Corp CSE:LXX OTCMKTS:LXRP revealed that its first human clinical trial assessing its DehydraTECH CBD technology to treat high blood pressure - HYPER-H21-1 - is now officially underway. It is the first of three clinical trials aimed at assessing this potential treatment, and dosing of human volunteers has begun, the company told investors. 